Development and clinical application of nasal mucosa vaccine in influenza virus

1）病毒antigen nucleus protein， rat peculiar CpG motif and the special cellulose·Extraction of the virus antigen nucleus protein ：We used it in the state that inactivated influenza virus PR8 （H3N2） by formalin。然后，我们通过液体色谱法在病毒薄膜中提取了存在的核蛋白，并通过Western blot方法确认了它，并使用了这种病毒抗核蛋白来制造疫苗。在疫苗本身或F344大鼠中的抗原核蛋白（七周老龄）的亚切或内注射后，我们收集了血液，在注射前和注射后正常和测量的感染抗体标题，并通过ELISA方法比较它们。我们确认，我在同一时间审查了CTL的活动能力，而且对主机一方免疫系统的指导已经失效。大鼠peculiar CpG Motif的设计：它被认为是CpG Motif，包括TGACGTT的排列，提高了免疫力。 ... More 最像B细胞的活动，细胞因子生产的一种方法，所以我们用它来做实验。我们通过ELISA方法对抗体质量进行了测量和测量，通过ELISA方法对细胞因子生产的数量进行了常规的血清和淋巴细胞检测，通过ELISPOT方法对CTL活性添加了细胞因子生产的数量. 2）流感病毒中的纳萨尔穆科斯疫苗的开发·对纳萨尔肌肉膜疫苗的反应性的测试：我们混合了病毒抗原核蛋白和CpG动机为1：1，并添加了两种类型的纤维素（羟基纤维素（HPC） 8：微晶体玻璃纤维素（MCC） 2）到它。最后，我们保持在一个天然洞穴中的比率和原子化。与液体疫苗进行比较：我们比较了液体疫苗和液体疫苗之间的影响，经调整到最适合密度的疫苗。实际上，液体疫苗在抗体生产（IgG/IgA）中的优先级， HA抗体标题，细胞细胞毒性功能的两个点。在这一警告中，它被确认为我们需要一个更深入的设备来进行临床试验研究，用于该代理的实际用途。However，有人认为，我们的疫苗具有75%的内源性和60%的亚切割性注射的影响。最后，我们决定在添加改进和编译结果的同时，将结果作为一篇文章（在新闻中）。然后，我们希望我们能为未来的外国国家杂志做出贡献。Less（低）

1) Mixture of virus antigen nucleus protein, rat peculiar CpG motif and the special cellulose・Extraction of the virus antigen nucleus protein :We used it in the state that inactivated influenza virus PR8 (H3N2) by formalin. Then, we extracted existing nucleus protein by liquid chromatography in this virus film and confirmed it by Western blot method and used this as virus antigen nucleus protein for vaccine making. After subcutaneous or intramuscular injection of inactivation vaccine itself or the antigen nucleus protein in F344 rats (seven-weeks old of age) as a laboratory animal, we collected blood after before and after injection regularly and measured influenza antibody titer of the sera by ELISA method and compared them. We confirmed that I examined CTL activity ability at the same time, and the instruction of the immune system of the host side was caused.・Design of rat peculiar CpG motif :It was recognized that CpG motif including the arrangement of TGACGTT raised an immunity eff … More ect most such as B cell activity, a cytokine production instruction, so we used it for an experiment. We collected sera and lymphocytes before and after injection regularly, and measured the antibody titer measurement by ELISA method, the quantity of cytokine production by ELISPOT method added to CTL activity.2) Development of the nasal mucosa vaccine in influenza virus・Examination of the reactivity of the nasal mucous membrane vaccine :We mixed virus antigen nucleus protein and CpG motif as 1:1, and added two kinds of cellulose ( hydroxypropyl cellulose (HPC) 8: microcrystal glass cellulose (MCC) 2) to it. Finally, we kept the ratio and atomized it in a nasal cavity.・Comparison with the liquid vaccine :We compared the effect between the inactivation liquid vaccine and the powdered vaccine which adjusted to the most suitable density. Actually, liquid vaccine superior to our vaccine in antibody production (IgG/IgA), HA antibody titer, both points of the cell cytotoxicity function. In this regard, it was recognized that we needed a further device to the clinical trial study of the practical use of this agent. However, it was suggested that our vaccine had the effect of 75% of intranasal and 60% of subcutaneous injection with liquid vaccine.Finally, we decided to go while adding improvement and compiled the result to the existing stage as an article (in press). And then, we hope that we contribute the study to foreign countries magazine in future. Less